9G6R

Fab-IP8 in complex with rocuronium

9G6R の概要

• エントリーDOI: 10.2210/pdb9g6r/pdb
• 分子名称: Fab-IP8 Heavy chain, Fab-IP8 Light chain, rocuronium, ... (4 entities in total)
• 機能のキーワード: immunotherapy, anaphylaxis, immune system
• 由来する生物種: Mus musculus; 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 48565.21

構造登録者

Haouz, A.,Saul, F.A.,Bruhns, P. (登録日: 2024-07-19, 公開日: 2025-02-12, 最終更新日: 2025-05-21)

主引用文献

Dejoux, A.,Zhu, Q.,Woolfe, A.,Godon, O.,Ellouze, S.,Mottet, G.,Castrillon, C.,Gillis, C.,Pecalvel, C.,Ganneau, C.,Iannascoli, B.,Lemoine, F.,Saul, F.,England, P.,Reber, L.L.,Gouel-Cheron, A.,de Chaisemartin, L.,Haouz, A.,Millot, G.A.,Bay, S.,Gerard, A.,Jonsson, F.,Chollet-Martin, S.,Bruhns, P.
Antibody-secreting cell repertoires hold high-affinity anti-rocuronium specificities that can induce anaphylaxis in vivo.
J.Allergy Clin.Immunol., 155:1557-1574, 2025

PubMed Abstract: Neuromuscular blocking agents (NMBA) are muscle relaxants used to assist mechanical ventilation but lead in 1/10,000 anesthesia to severe acute hypersensitivity reactions i.e., anaphylaxis. Incidences vary between types of NMBAs. Rocuronium, a widely used non-depolarizing aminosteroid NMBA, induces among the highest anaphylaxis rates. Rocuronium-induced anaphylaxis is proposed to rely on pre-existing rocuronium-binding antibodies, but no such antibodies have ever been identified.

PubMed: 39892658
DOI: 10.1016/j.jaci.2025.01.025

実験手法

X-RAY DIFFRACTION (1.72 Å)